U.S. Government Orders 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic

Bavarian Nordic A/S announced that the U.S. BARDA also known as Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, has ordered an additional 2.5M (Million) doses of liquid-frozen JYNNEOS, a non-replicating smallpox vaccine and the only vaccine against monkeypox, which is approved by the FDA. 

So far, approximately 1,470 cases of monkeypox, which can cause skin lesions and flu-like symptoms, have been reported in the country, mostly among men who have sex with men. 

Health officials forecast an increase in cases in the coming days due in part to increased reporting of the disease and more testing, US CDC Director Rochelle Walensky uttered in a press briefing.

No cases of monkeypox have been identified among adolescents in the country since testing was expanded to commercial labs last week, she said.

The new order follows a couple of previous orders from the Biomedical Advanced Research and Development Authority in June and July 2022 for 500,000 and 2.5 Million doses respectively, together with an order from the Biomedical Advanced Research and Development Authority in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to around 7 million doses.

This extra order will be filled at the US-based contract manufacturer using bulk vaccines already manufactured and invoiced under previous contracts with Biomedical Advanced Research and Development Authority and currently stored at Bavarian Nordic. A tech transfer of the process to the contract manufacturer will begin promptly, with the aim to manufacture all doses under this contract in 2022.

According to Paul Chaplin, President, and CEO of Bavarian Nordic, “Enhancing our manufacturing potential into the US enables the company to deliver more vaccines of Monkeypox in order to match the immediate worldwide requirement for JYNNEOS. This immediate response to a serious health crisis is only possible because the Government of the US is diligent in long-term planning for their national preparedness.”

About Bavarian Nordic:

Bavarian Nordic, is a fully integrated vaccine firm that is focused on the manufacturing, development, and commercialization of life-saving vaccines. Bavarian Nordic is a global leader in smallpox vaccines and has been a prolific supplier to the Government of the U.S of a non-replicating smallpox vaccine, authorized by the Food and Drug Administration, also for the protection against monkeypox. The vaccine is also authorized in order to protect against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe. The company's commercial product portfolio furthermore contains the top-most vaccines against tick-borne encephalitis and rabies. Using their live virus vaccine program, MVA-BN, they have established a diverse portfolio of proprietary and partnered product candidates designed in order to save and improve lives by unfastening the power of the defense system, including an Ebola vaccine, licensed to the Janssen Pharma Companies of Johnson & Johnson. Bavarian Nordic is also committed to the development of a next-generation vaccine for COVID-19.

Factors Associated with Adherence to Oral Kahler's Disease Therapy

Shortfall of adherence to cancer treatment comprising oral therapies can contribute to poor treatment findings, and researchers carried out a study to probe factors that may be associated with lack of adherence to oral agents. 

Wilbur Rutter, Ph.D., PharmD, of CVS Health in Lincoln, Rhode Island, and colleagues presented the study’s outcomes in a poster at the American Society of Clinical Oncology Annual Meeting 2022.

In this carried out study, Dr. Rutter and colleagues did a retrospective review of records from patients with newly diagnosed Kahler's Disease also named multiple myeloma (MM) who were being treated with the help of oral agents during the time span of 01/09/2016, through 01/09/2020. 

Adherence to therapy was the finding of interest, which was elaborated as having an annual medicine possession ratio of 0.8-1.2. A socioeconomic status (SES) composite index (created by researchers), was developed from data acquired at the zip-code level.

Researchers did a multivariable regression investigation of adherence with factors including the socioeconomic status-index and demographic deets.

On behalf of the socioeconomic status index, patients were grouped as Very Low, Low, Medium, High, and Very High groups. It reflected rising levels of zip code-based median household income as socioeconomic status-index values rose from very low to very high. It also aligned with US CDC Social Vulnerability Index (SVI) scores, reflecting greater vulnerability with minor socioeconomic status.

Carried out study included a total of 6602 patients, 64.5 percent of whom were adherent. Adherent patients were compared with non-adherent patients. 

The multivariable evaluation suggested several evaluated factors demonstrated significant, independent link-ups with adherence. Regarding adherence based on socioeconomic status-index scores, the researchers considered patients with a very low socioeconomic status index to show a significantly lower rate of adherence than seen in patients having a very high socioeconomic status index.

The increasing age was related to greater adherence, although polypharmacy was related to less adherence.

Compared with lacking polypharmacy, patients with mild polypharmacy were less likely to be adherent. Moderate polypharmacy was also related to nonadherence, as was significantly polypharmacy.

Conclusion: Researchers concluded there were not any specific relationships with adherence across maximum socioeconomic status indexes, but that patients in Very Low socioeconomic status zip codes demonstrated less adherence than patients in Very High socioeconomic status zip codes did. Polypharmacy and younger age were other factors researchers considered linked to worse adherence.

Atracurium Besylate: Precautions and Warnings

 

Atracurium Besylate is a nondepolarizing neuromuscular blocker, also known as an immune suppressor. Atracurium Besylate is used in the treatment of lymphoma, multiple myeloma, leukaemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. Atracurium Besylate is supplied in 25 mg in 2.5ml single-use vials to administer intravenously. One should read the warnings and precautions associated with Atracurium Besylate, such as: 

Atracurium Besylate has been associated with residual paralysis. Patients with neuromuscular diseases and carcinomatosis may be at higher risk of residual paralysis. To prevent complications resulting from Atracurium Besylate-associated residual paralysis, extubation is recommended only after the patient has recovered sufficiently from neuromuscular blockade.

Serious adverse reactions, including “gasping syndrome”, can happen in neonates and infants treated with benzyl alcohol-preserved drugs, including Atracurium Besylate. When prescribing the doses of Atracurium Besylate vials in infants, consider the combined daily metabolic load of benzyl alcohol from all sources, including Atracurium Besylate and other drugs containing benzyl alcohol. 

Patients treated with Atracurium Besylate with renal or hepatic impairment might have higher metabolite concentrations than patients with normal renal and hepatic function. The level of neuromuscular blockade during long-term Atracurium Besylate administration should be monitored with a nerve stimulator to titrate the drug Atracurium Besylate administration to the patients’ needs and limit exposure to toxic metabolites.

There are reports of severe hypersensitivity reactions, including fatal and life-threatening anaphylactic reactions after administration of Atracurium Besylate injection. Due to the potential severity of such reactions, one should take appropriate precautions, such as the immediate availability of appropriate emergency treatment. 

Administration of Atracurium Besylate results in paralysis, leading to respiratory arrest and death, a progression that may likely happen in a patient for whom it is not intended. One should confirm the proper selection of the intended product and avoid confusion with other injectable solutions in critical care and other clinical settings.

Neuromuscular blockade in the conscious patient could lead to distress. Use Atracurium Besylate in the presence of appropriate sedation or general anaesthesia. One should monitor patients to ensure that the level of anaesthesia is adequate. 

Certain drugs might enhance the neuromuscular blocking action of Atracurium Besylate, including inhalational anaesthetics, antibiotics, magnesium salts, lithium, local anaesthetics, procainamide, and quinidine. One should use peripheral nerve stimulation and monitor the clinical signs of neuromuscular blockade to determine the adequacy of the level of neuromuscular blockade and the need to adjust the Atracurium Besylate dosage.

  

Note: All information mentioned in this article is provided just for informational, educational, and referential purposes only.

Abciximab: A New Antiaggregant For Angioplasty

Abciximab is licensed as the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. It is involved in binding to the glycoprotein (GP) Ilb/Illa receptor of the human platelets and inhibits platelet aggregation. Abciximab is also involved in binding to the vitronectin receptor typically found on the platelets and vessel wall endothelial and smooth muscle cells. This medicinal product is prescribed when you undergo an operation known as angioplasty for the following purposes: 

• Abciximab is prescribed (along with heparin and aspirin) for the prevention of the formation of blood clots in the heart while on or after an angioplasty operation. 
• Abciximab is also prescribed (along with heparin and aspirin) to reduce the short term risk of getting a heart attack prior to an angioplasty operation, which is planned to take place within the next 1-month. This is for those who have chest pain due to low blood supply to the heart (unstable angina) and have not responded to the usual therapy.

What Abciximab Does?

As an active ingredient, abciximab is a fragment of murine or human chimeric monoclonal antibody, which are specific proteins that recognize and bind to other unique proteins. Abciximab falls under the group of medications known as antithrombotics and binds to platelets in the blood in order to help prevent blood clots. 

Posology and Method of Administration

Abciximab is introduced for intravenous administration in adult patients. It should only be used in conjunction with extensive health specialist care. In addition, there must be the existence of laboratory tests of hematology function as well as facilities for administration of blood products.

The recommended dose of abciximab injection is a 0.25 mg/kg intravenous bolus promptly followed by a 0.125 µg/kg/min (to a maximum of 10 µg/min) continuous intravenous infusion.

For the stabilization of unstable angina patients, the bolus dose of abciximab followed by the infusion needs to be initiated up to 24 hours before the possible intervention and concluded 12 hours following the intervention.

In order to prevent ischemic cardiac complications in such patients who are undergoing percutaneous coronary intervention, and are not currently receiving a Abciximab infusion, the bolus needs to be administered 10 to 60 minutes before intervention followed by the infusion for 12 hours.

Adverse Effects due to Abciximab

The most commonly reported adverse effects due to abciximab injection are hypotension, injection site pain, chest pain, abdominal pain, vomiting, minor hemorrhage, nausea, gross hematuria, and backache.

Some rare but severe side effects due to abciximab may include anaphylaxis, major hemorrhage (cerebrovascular, pulmonary), thrombocytopenia, and non-hemorrhagic cerebrovascular accident.

The administration of Abciximab is not associated with an increased risk of bleeding in patients undergoing CABG treatment.

Warnings And Precautions

Therapy with abciximab may be responsible for increasing the risk of bleeding, particularly in case you are receiving other medicines for preventing your blood from clotting (blood thinners). Cases of death because of bleeding have been noted with the administration of Abciximab. Prior to starting treatment with Abciximab discuss with your health specialist:

• In case you are taking blood-thinner or any other drugs that affect blood clotting or blood platelets. 
• In case you have previously received abciximab, since this could be linked with increased risk of reduction in blood platelets or allergic reactions (hypersensitivity). 
• In case you are pregnant or want to become pregnant or are breast-feeding. Your healthcare specialist can discuss with you the possible risks and benefits involved. 
• In case you think that you fit into any of the above-mentioned categories, it is crucial that you discuss it with your health specialist

Interactions with Abciximab

Medicines that may interact with Abciximab 10 MG /5ML include: Blood-thinners, or any other medications that are responsible for affecting blood clotting (anticoagulants) or blood platelets (‘antiplatelet drugs). It is quite necessary that you inform your health specialist if thrombolytic agents have been given to unblock your arteries. Being given Abciximab injection 10mg/5mL along with these medications may be responsible for putting you at risk of increased bleeding.

Storage and Availability

Currently, Abciximab is a prescription-only medication typically available as an intravenous (IV) solution. Vials of Abciximab should be stored at 2°C to 8°C (36°F to 46°F). Neither freeze nor shake the vials. Never use it beyond the date of expiry. Unused portions left in the vial should be discarded. In India, the abciximab price is absolutely reasonable. In order to procure this medicinal product at the most reasonable price range, one can directly get in touch with us through TOLL-FREE: 1800-889-1064. We're authentically established WHO-GDP and ISO certified pharmaceutical wholesaler/supplier/distributor, based in India. 

NOTE: Deets mentioned in this article about "Abciximab: A New Antiaggregant Used in Angioplasty" is for informational or educational purposes only, and does not substitute professional medical advice or consultations with health specialists.

Infliximab for AutoImmune Disease

Infliximab is a medication approved to treat several conditions including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis. Prior to starting treatment, patients should discuss both benefits and risks of taking infliximab 100 mg injection with your healthcare team. And that way, patients can make an informed decision.

What is infliximab?

Infliximab is a sort of medicine known as biological therapy. It can be prescribed for conditions:

• Rheumatoid arthritis 
• Crohn’s Disease
• Plaque psoriasis
• Psoriatic arthritis 
• ulcerative colitis
• axial spondyloarthritis, including ankylosing spondylitis.

In a few cases, health specialists may prescribe Infliximab Injection for treating certain sorts of vasculitis too. In RA and some other conditions, an excess protein named TNF is developed in the body. This is responsible for causing inflammation, pain, and destruction to your joints. Anti-TNF medicines, such as infliximab, inhibit TNF and scaled-down this inflammation.

Anti-TNF medicines, such as infliximab, are basically not painkillers. They change or resist how your disease affects your body. Your signs and symptoms should start to improve within 2 to 12 weeks of initiating therapy with infliximab.

Who Can Take?

There are some guidelines about when infliximab 100 mg injection can be used. It varies depending on which type of condition you have. You won’t be prescribed infliximab if you haven’t tried certain other suitable medicines first.

Infliximab therapy won’t be initiated if:

• your disease isn’t active
• you haven’t tried other therapies for your disease first
• you have an infection. 

Before you’re prescribed the medicine infliximab, health specialists sometimes use a scoring system for evaluating how many of your joints are painful or swollen and how it makes you feel. This favors them to work out how seriously active your arthritis is.

You’ll also require blood tests prior to treatment in order to see whether the medicine is suitable for you.

Your health specialists will also assess whether you’ve had tuberculosis (TB) and hepatitis infections. This is because infliximab 100 mg can increase the probability of these starting up again. In case you test +ve for either of these, you may require therapy prior to starting infliximab. 

Your health specialists may also prescribe an HIV test. In case you have HIV, this should be well controlled prior to starting infliximab therapy. 

Your health specialists may decide not to prescribe the drug infliximab in case you’ve had or have:

• any active infection, or repeated/serious infections 
• multiple sclerosis or there’s history of multiple sclerosis in your immediate family
• cancer 
• certain heart conditions 
• scarring of the lung tissue, called pulmonary fibrosis. 

In case infliximab isn’t suitable, your health specialists will discuss other existing treatment options with you.

Dosage & Administration

The infliximab injection is usually administered through a drip into a vein. This is named an intravenous infusion. It’s usually performed in a hospital and takes around a couple of hours. You’ll need to wait for another hour or two prior to leave in case you experience any side effects. 

Recommended Dose for Crohn’s Disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adults who initially respond to therapy may benefit from enhancing the dose to 10 mg per kg if they later lose their response. 

Recommended Dose for Pediatric Crohn’s Disease: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. 

Recommended Dose for Ulcerative Colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. 

Recommended Dose for Pediatric Ulcerative Colitis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. 

Recommended Dose for Rheumatoid Arthritis: In conjunction with drug methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. A few patients may benefit from enhancing the dose up to 10 mg per kg or treating as often as every 4 weeks. 

Recommended Dose for Ankylosing Spondylitis: 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks. 

Recommended Dose for Psoriatic Arthritis and Plaque Psoriasis: 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.

Once you’ve been on the therapy for a while, the infliximab infusion may take less time. Because it’s a long-term therapy, it’s necessary to keep having your infusions of infliximab, even if it doesn’t seem to be effective at first. You’ll also should keep taking it when your signs and symptoms start to improve, to help keep the disease under control. In a few cases, you may take the biosimilar as an injection instead.

Infliximab Side effects and Risks

Like all medicines, infliximab can sometimes cause some side effects. Some commonly reported side effects due to infliximab injection include:

• a blocked or runny nose
• headaches
• dizziness
• flushing
• a rash
• stomach pain
• indigestion
• feeling sick

A rapid or irregular heartbeat is also quite common; you should discuss with your health specialist if this happens to you.

Because this medication affects the immune system, it can be responsible for making you more likely to catch infections. In rare cases, the body might not develop enough of the blood cells that help to fight infections or stop bleeding. 

Inform your rheumatology health specialist straight away in case you develop any signs or symptoms of infection. These include a fever or sore throat, or any other new signs and symptoms that concern you. 

If any of these signs and symptoms are severe, your treatment may need to be interrupted. Your health specialist may also recommend that you temporarily interrupt infliximab therapy if you're on antibiotics. 

You also need to see your health specialist if you develop chickenpox or shingles, or in case you come into contact with anyone who has chickenpox or shingles. These infections may be severe in case you’re on infliximab 100 mg. You may require antiviral therapy, and your treatment may be stopped until you’re better.

Some individuals may have a -ve reaction to the infusion. This is more likely while on or soon after the initial few infusions.

Storage & Price

Store the vials of infliximab between 2 & 8 deg C. The infusion should start within 3 hours following the preparation and the solution need not be stored for reuse (because of the potential for microbiological hazard, and the absence of any preservative).

The infliximab price in India is absolutely less than other countries. The prices of infliximab typically fluctuates from generic to brand-name medicinal products. The generic forms of infliximab tend to cost very less than their available equivalents. The generic forms of the biologic drug infliximab appear to be just as safe and effective as the brand name version. Kindly connect to us at TOLL-FREE: 1800-889-1064 to get this medicinal product authentically. 

Ibrutinib (Imbruvica) Enhances Survival for Younger Individuals with Diffuse Large B-cell Lymphoma

 

Addition of ibrutinib (Imbruvica) to a standard chemotherapy regimen can enhance survival for some younger individuals with a specific form of diffuse large B-cell lymphoma (DLBCL), as per the reanalysis of data.

The findings, published in the Journal Cancer Cell, come from a new analysis by researchers at the USA’s National Cancer Institute (NCI) of a previously conducted phase-3 clinical trial.

 

Diffuse large B-cell lymphoma is the most common type of lymphoma, accounting for 40 percent of lymphoma cases at the global level. The individuals with the diffuse large B-cell lymphoma are typically treated with R-CHOP, which includes vincristine, cyclophosphamide, doxorubicin, prednisone, and the monoclonal antibody rituximab. But R-CHOP therapy is not useful for everyone with diffuse large B-cell lymphoma.

 

Ibrutinib (Imbruvica) was the first targeted therapy to be assessed for the treatment of diffuse large B-cell lymphoma. It inhibits the function of Bruton tyrosine kinase, a protein that is involved in the growth and survival of B cells. Cancerous cells of the ‘active B cell-like’ (ABC) subtype of diffuse large B-cell lymphoma require this protein in order to survive.

 

A trial named PHOENIX was launched in the year of 2013 to assess the effectiveness of adding ibrutinib to R-CHOP therapy for newly diagnosed patients which do not have the ‘germinal centre B cell–like’ (GCB) type of diffuse large B-cell lymphoma.

 

Outcomes published in 2019 demonstrated that overall, combination of ibrutinib and standard chemotherapy regimen did not help patients with non-germinal centre B cell–like diffuse large B-cell lymphoma in order to live longer.

 

Although, patients aged under 60 years did have improved event-free survival and overall survival, but as this was a secondary endpoint of the trial its significance has remained controversial.

 

Therefore, in this latest study, researchers of the National Cancer Institute as well as their collaborators evaluated the tumour biopsy samples from patients on the trial.

 

They have now concluded that patients aged under 60 years with MCD and N1, specific genetic subtypes of non-germinal centre B cell–like diffuse large B-cell lymphoma, had an exceptional response to the combined therapy or treatment.

All of those patients are alive without disease 3 years following diagnosis.

According to Study co-author Dr Wyndham H. Wilson, senior investigator in the Lymphoid Malignancies Branch, “This new analysis offers a compelling rationale for health specialists to consider addition of ibrutinib (Imbruvica) along with the standard chemotherapy for the initial therapy of younger individuals with non-germinal centre B cell–like diffuse large B-cell lymphoma.”

 

Following the completion of genetic analyses on tumour samples from 773 of the 838 participants and determining their subtypes, researchers found that most of the benefit from ibrutinib (Imbruvica) was in patients with ABC diffuse large B-cell lymphoma.

 

Out of the 4 genetic subtypes of ABC diffuse large B-cell lymphoma, it was found that those patients aged 60 and under with the MCD subtype had 3-year event free and OS rates of 100 percent with ibrutinib (Imbruvica) and R-CHOP. This is compared to 3-year event free survival of 48 percent and 3-year OS of 69.6 percent with R-CHOP alone.

 

Younger individuals with the N1 subtype also had 3-year event-free and OS (overall survival) rates of 100 percent with ibrutinib (Imbruvica) and R-CHOP, in comparison to 3-year event-free and OS of 50 percent with R-CHOP alone.

Individuals with the genetic subtype named BN2 did not benefit from the addition of the ibrutinib (Imbruvica), but this subtype already has an 82 percent OS rate with R-CHOP alone.

Ibrutinib (Imbruvica) was also effective for some other younger individuals with the non-germinal centre B cell–like diffuse large B-cell lymphoma, although the researchers were not able to specify benefits for the A53 subtype.

According to Dr Louis M. Staudt, chief of the Lymphoid Malignancies Branch in the Center for Cancer Research at NCI, “For years we have only had chemotherapy and rituximab to offer these individuals (patients). Now, we expect that the addition of ibrutinib (Imbruvica) to current therapy may provide younger patients a better chance of surviving this aggressive cancer.”

Dosage and Administration of Artesunate

 

Indications & Usage: Artesunate for Injection (Injectable artesunate) is introduced as a first line treatment and recommended by WHO for the initial treatment of severe malaria in adult as well as pediatric patients.

In order to treat severe malaria with injectable artesunate should always be followed by a full or complete treatment course of an apt oral antimalarial regimen.

Limitations of Use: The artesunate an anti-malaria medication does not treat the hypnozoite liver stage forms of Plasmodium and will therefore not prevent the relapses of malaria because of the Plasmodium vivax or Plasmodium ovale. Concomitant therapy with an antimalarial agent such as an 8-aminoquinoline drug is required for treating the severe malaria due to P. vivax or P. ovale.

 

Dosage Forms and Strengths: The injectable artesunate is available as the strength of 110 mg for Injection. It comes as a sterile white or almost white, fine crystalline powder in a clear glass single-dose vial for constitution.

 

Dosage and Administration: The recommended dosage and administration of Artesunate for Injection in adult and pediatric patients is 2.4 mg/kg administered, should be intravenously at 0 hours, 12 hours, and 24 hours, and thereafter, administered once daily until the patient is able to tolerate the oral antimalarial therapy. Administer constituted artesunate injection intravenously as a slow bolus over one minute to two minutes. Do not administer artesunate injection via continuous intravenous infusion. The artesunate injection should be administered with an antimalarial agent that is active against the hypnozoite liver stage forms of Plasmodium, such as an 8-aminoquinoline drug, to patients with the severe malaria due to P. vivax or P. ovale.

 

Preparation of Artesunate for Injection for Intravenous Administration: The Artesunate Injection needs to be constituted with the supplied diluent before administration. A diluent consisting of 12 mL of sterile 0.3 M pH 8.0 sodium phosphate buffer is provided with Artesunate for Injection.

To constitute artesunate injection, withdraw 11mL of this diluent through a needle and syringe and inject into the artesunate vial (when constituted the final concentration of artesunate is 10 mg/mL). Swirl gently (avoid shaking) for up to five to six minutes until the powder is completely dissolved and no visible particles remain.

The parenteral drug products need to be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit. It is not advised to administer the Artesunate for Injection in case particulate matter and/or discoloration is observed.

Following constitution, inject the constituted solution intravenously (through an established intravenous line or needle) as a slow bolus over one to two minutes. It is advised to discard the vial and also any unused portion of the medicine product following use.

 

Storage of the Constituted Solution: The constituted solution of Artesunate Injection should be administered within 1.5 hours of constitution with the supplied diluent.